natgillin/translations-raw huggingface dataset:
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Imetnik dovoljenja za promet mora Evropsko komisijo obvestiti o marketinškem načrtu za zdravilo,
Do not use in cases of hypersensitivity to cephalosporin or penicillin antibiotics.
Ne uporabite v primerih preobčutljivosti na cefalosporinske ali penicilinske antibiotike.
Before reconstitution:
Pred rekonstitucijo:
In the event of contact, wash skin with soap and water.
V primeru stika, operite kožo z vodo in milom.
It is, therefore, advisable to determine the underlying cause and to treat the animal accordingly.
Priporočljivo je, da določite vzrok primarne bolezni ter temu primerno zdravite žival.
(2003 survey)
(2003 poročilo)
As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with Porphyromonas spp.
Kot dodatno zdravljenje pri mehaničnih ali kirurških periodontalnih terapijah pri zdravljenju resnih infekcij dlesni in periodontalnega tkiva povezanih s Porphyromonas spp.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated ) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
BESEDILO “SAMO ZA ŽIVALI” IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, ČE JE SMISELNO
Plasma protein binding is high (more than 99 %) and the volume of distribution is low (0.09 l/kg).
Vezava na plazemske proteine je visoka (več kot 99 %), volumen distribucije pa nizek (0,09 l/kg).
No. of Isolates cefovecin MIC (µg/ml)
Št. izolatov cefovecin MIC (µg/ml)
TARGET SPECIES Dogs and cats.
CILJNE ŽIVALSKE VRSTE Psi in mačke.
Disposal: read package leaflet.
Odstranjevanje: preberite navodilo za uporabo.
Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa.
Preobčutljivost na peniciline lahko vodi do navzkrižne občutljivosti na cefalosporine in obratno.
Resistance may be chromosomal or plasmid-encoded and may be transferred if associated with transposons or plasmids.
Rezistenca je lahko povezana s kromosomi ali plazmidi in se lahko prenese, če je vezana na transpozone ali plazmide.
The fundamental requirement of the treatment of periodontal disease is mechanical and/or surgical intervention by the veterinarian.
Osnovni pogoj pri zdravljenju periodontalnega obolenja je veterinarski mehanični in/ali kirurški poseg.
Shake the vial until the powder is seen to have fully dissolved.
Vialo pretresajte, dokler se prašek popolnoma ne raztopi.
Pyoderma is often secondary to an underlying disease.
Pioderma je pogosto sekundarni klinični znak osnovne bolezni.
Manufacturer responsible for batch release: Haupt Pharma Latina S.r.l.
Izdelovalec, odgovoren za sproščanje serij: Haupt Pharma Latina S.r.l.
The safety of Convenia has not been assessed in animals suffering from severe renal dysfunction.
Varnost zdravila Convenia ni bila dokazana pri živalih z okvaro ledvic.
In accordance with good veterinary practice, treatment of pyoderma should be extended beyond complete resolution of clinical signs.
V skladu z dobro veterinarsko prakso je potrebno piodermo zdraviti še po prenehanju kliničnih znakov.
Treated animals should not be used for breeding for 12 weeks after the last administration.
Zdravljene živali niso za razplod 12 tednov po zadnjem dajanju zdravila.
4.4 Special warnings for each target species
4.4 Posebna opozorila za vsako ciljno živalsko vrsto
Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations.
Izogibajte se stiku z zdravilom, če veste, da ste preobčutljivi ali vam je bilo svetovano, da ne delate s takimi preparati.
Plasma protein binding is high (96.0 % to 98.7 %) and the volume of distribution is low (0.1 l/kg).
Vezava na plazemske proteine je visoka (96,0 % do 98,7 %), volumen distribucije pa nizek (0,1 l/kg).
If you know you are allergic to penicillins or cephalosporins, avoid contact with contaminated litter.
Če ste alergični na peniciline ali cefalosporine, se izogibajte stika s kontaminiranimi odpadki.
The safety of Convenia in dogs and cats has not been established during pregnancy and lactation.
Varnost zdravila pri psicah in mačkah v obdobju brejosti in laktacije ni bila ugotovljena.
As with all cephalosporins, the action of cefovecin results from the inhibition of bacterial cell wall synthesis; cefovecin has bactericidal activity.
Kot vsi cefalosporini, cefovecin deluje tako, da inhibira sintezo celične stene bakterije; cefovecin ima baktericidni učinek.
Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injection
Natrijev hidroksid (za uravnavo pH) Klorovodikova kislina (za uravnavo pH) Voda za injekcije
Cefovecin is a third generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria.
Cefovecin je cefalosporin tretje generacije s širokim spektrom delovanja proti grampozitivnim in gramnegativnim bakterijam.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2006
Datum pridobitve dovoljenja za promet: 19/06/2006 Datum zadnjega podaljšanja dovoljenja za promet: 15/06/2011
A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site.
Enkratno dajanje 22,5-kratnega priporočenega odmerka je povzročila prehodni edem in neugodje na mestu injiciranja.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na zunanji ovojnini.
If required, treatment may be repeated at 14 day intervals up to a further three times.
Če je potrebno, zdravljenje ponovite do trikrat s 14-dnevnimi presledki.
Anaerobic bacteria such as Bacteroides spp.
Anaerobne bakterije, kot so Bacteroides spp.
Cefovecin has unique pharmacokinetic properties with extremely long elimination half-lives in both dogs and cats.
Cefovecin ima edinstvene farmakokinetične lastnosti z zelo dolgo razpolovno dobo izločitve pri psih in mačkah.
Not applicable.
Ni smiselna.
Store in the original package in order to protect from light.
Shranjujte v originalni ovojnini, za zaščito pred svetlobo.
Special precautions for use in animals:
Posebni previdnostni ukrepi za uporabo pri živalih:
Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production) or from other mechanisms.
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze) ali drugih mehanizmov.
Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated.
Resne akutne preobčutljivostne reakcije lahko zahtevajo zdravljenje z epinefrinom in ostalimi nujnimi ukrepi, vključno s kisikom, intravenskimi tekočinami, intravenskim antihistaminikom, kortikosteroidi in inhalacijsko terapijo, kot je klinično indicirano.
Active substance:
Pomožne snovi:
The antimicrobial activity of Convenia following a single injection lasts for up to 14 days.
Protimikrobno delovanje zdravila Convenia po enkratnem injiciranju traja do 14 dni.
Following repeated administrations at the recommended dose, elevated concentrations of cefovecin were observed in plasma.
Po ponovnem dajanju priporočenega odmerka, so bile v plazmi opažene povišane koncentracije cefovecina.
Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production), from reduced permeability by porin mutations or change in efflux, or by selection of low-affinity penicillin-binding proteins.
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze), zmanjšane propustnosti zaradi mutacij ali sprememb izliva proteina porin ali zaradi izbire za vezavo penicilinov manj privlačnih proteinov.
Pharmacotherapeutic group: Antibacterials for systemic use (cephalosporins).
Farmakoterapevtska skupina: Antibiotiki za sistemsko uporabo (cefalosporini).
Cross resistance with other cephalosporins and other beta-lactam antibacterial agents can be observed.
Navzkrižna rezistenca z ostalimi cefalosporini in beta laktamskimi antibiotiki je lahko prisotna.
INDICATION(S) For certain skin, soft tissue, urinary tract and severe periodontal infections.
Določene infekcije kože, mehkega tkiva, urinarnega trakta in resne periodontalne infekcije.
It differs from other cephalosporins in that it is highly protein bound and has a long duration of activity.
Od ostalih cefalosporinov se razlikuje po tem, da se močno veže na proteine in ima podaljšano delovanje.
Dog Cat Pasteurella multocida Dog Cat
Pasteurella multocida pes maček
QUANTITY OF THE ACTIVE SUBSTANCE(S) Each vial contains 852 mg cefovecin.
Vsaka viala vsebuje 852 mg cefovecina.
The powder is off-white to yellow and the diluent (solvent) is a clear, colourless liquid.
Prašek je sivo bele do rumene barve, vehikel je jasna, brezbarvna tekočina.
Reconstitution yields either 4 ml or 10 ml of solution for injection respectively.
Po rekonstituciji dobite 4 ml oziroma 10 ml raztopine za injiciranje.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
EU/2/06/059/002 (5 ml)
EU/2/06/059/001(23 ml) EU/2/06/059/002 (5 ml)
If an allergic reaction occurs, no further administrations of cefovecin should be administered and appropriate therapy for beta-lactam hypersensitivity should be instituted.
Če se pojavi alergična reakcija, je potrebno prekiniti z dajanjem cefovecina ter začeti s primerno terapijo proti beta-laktamski preobčutljivosti.
Pack size: 1 vial of powder and 1 vial of diluent.
Pakiranje: 1 viala praška in 1 viala vehikla.
ADVICE ON CORRECT ADMINISTRATION
NASVET O PRAVILNI UPORABI ZDRAVILA
Concurrent use of other substances that have a high degree of protein binding (e.g. furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse effects.
Sočasna uporaba zdravil, ki imajo visoko stopnjo vezave na proteine (npr. furosemid, ketokonazol ali nesteroidna protivnetna zdravila (NSAID)), lahko konkurira z vezavo cefovecina in tako povzroči neželene učinke.
Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs.
Posebna previdnost je potrebna pri pacientih, pri katerih se je že pokazala preobčutljivostna reakcija na cefovecin, cefalosporine, peniciline ali ostala zdravila.
It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins.
Priporočljivo je, da cefalosporine tretje generacije uporabite za zdravljenje kliničnih stanj, ki so slabo reagirala ali se pričakuje, da bodo slabo reagirala, na ostale antibiotike ali prvo generacijo cefalosporinov.
Shelf-life after reconstitution according to directions: 28 days.
Rok uporabnosti po rekonstituciji v skladu z navodili: 28 dni
After reconstitution, use within 28 days.
Rekonstituirano zdravilo uporabite v 28 dneh.
Pseudomonas spp., Enterococcus spp., and Bordetella bronchiseptica isolates are inherently resistant to cefovecin.
Pseudomonas spp., Enterococcus spp., in Bordetella bronchiseptica izolati so že naravno rezistentni na cefovecin.
Special precautions for use in animals
Posebni previdnostni ukrepi za uporabo pri živalih
On very rare occasions gastrointestinal signs, including emesis and/or diarrhoea, have been observed.
V zelo redkih primerih so bili opaženi znaki gastrointestinalnih motenj s slabostjo in/ali drisko.
PACKAGE SIZE 10 ml (after reconstitution) 4 ml (after reconstitution)
10 ml (po rekonstituciji) 4 ml (po rekonstituciji)
CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV
Peak concentrations in tissue cage fluid of 31.9 μg/ml were measured 2 days after administration.
Vrh koncentracije 31,9 µg/ml v tekočini tkivne kletke je bil izmerjen 2 dni po dajanju.
In-vitro activity against these pathogens as well as against other skin and urinary tract pathogens collected during a European (Denmark, France, Germany, Italy and United Kingdom) MIC survey (1999 - 2000)
In-vitro učinkovitost proti tem patogenom kot tudi proti ostalim patogenom kože in urinarnega trakta, ki so bili zbrani med evropskim (Danska, Francija, Nemčija, Italija in Velika Britanija) MIC pregledom (1999 - 2000) ter med evropskimi (Francija, Nemčija, Španija in Velika Britanija) kliničnimi študijami glede učinkovitosti in varnosti (2001 - 2003), je predstavljena v spodnji preglednici.
In very rare cases neurological signs and injection site reactions have been reported after the use of the product.
V zelo redkih primerih so po uporabi zdravila poročali o nevroloških simptomih in reakcijah na mestu injiciranja.
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact.
Penicilini in cefalosporini lahko povzročijo preobčutljivost (alergijo) po injiciranju, inhalaciji, zaužitju ali kontaktu s kožo.
The percentage of cefovecin resistant isolates in E. coli, Prevotella oralis, Bacteroides spp.
Deleži na cefovecin rezistentnih izolatov pri E. coli, Prevotella oralis, Bacteroides spp.
Powder and solvent for solution for injection.
Prašek in vehikel za raztopino za injiciranje.
and Prevotella spp.
in Prevotella spp.
Cat
maček
Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Pri pojavu resnejših kliničnih znakov, kot so otekanje obraza, ustnic, vek ali težav pri dihanju, je potrebno takoj poiskati zdravniško pomoč.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
BESEDILO “SAMO ZA ŽIVALI” Samo za živali.
Dog Cat
pes maček
Porphyromonas gingivalis and Prevotella intermedia collected from canine periodontal disease were also shown to be susceptible.
Porphyromonas gingivalis in Prevotela intermedia, ki so bile izolirane pri periodontalnem obolenju psov, so prav tako občutljive.
To ensure a correct dosage, body weight should be determined as accurately as possible to avoid underdosing.
Da bi zagotovili pravilen odmerek ter se izognili premajhnemu odmerjanju, čimbolj natančno določite težo živali.
At fourteen days after administration, urine concentrations were 2.9 μg/ml.
Štirinajst dni po dajanju je bila koncentracija v urinu 2,9 µg/ml.
MARKETING AUTHORISATION NUMBER(S) EU/2/06/059/001 (23 ml vial) EU/2/06/059/002 (5 ml vial)
EU/2/06/059/001 (23 ml viala) EU/2/06/059/002 (5 ml viala)
Skin and soft tissue infections in dogs:
Infekcije kože in mehkega tkiva pri psih:
Coagulase positive Staphylococcus spp.3, 4
Koagulaza pozitivni Staphylococcus spp.3, 4
The product is available in a single pack of either 5 ml or 23 ml, composed of a vial containing the freezedried powder, and a second vial containing the diluent.
Zdravilo je na voljo v posameznem pakiranju z eno 5- ali 23-mililitrsko vialo, ki vsebuje liofiliziran prašek, in eno vialo z vehiklom.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Penicilini in cefalosporini lahko povzročijo preobčutljivost (alergijo) po injiciranju, inhalaciji, zaužitju ali kontaktu s kožo.
MANUFACTURER'S BATCH NUMBER Lot: {number}
IZDELOVALČEVA ŠTEVILKA SERIJE
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo:
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
Za zdravljenje infekcije urinarnega trakta povezane z Escherichia coli in/ali Proteus spp.
Dog 29 ≤0.008
maček 24 ≤0,06
However, if stored as recommended, potency is not affected.
Če zdravilo hranite v skladu z navodili, je učinkovitost nespremenjena.
13 mg/ml benzyl alcohol
13 mg/ml benzilalkohola
Each 5 ml vial of lyophilised powder contains:
Ena 5 ml viala z liofiliziranim praškom vsebuje:
852 mg cefovecin (as sodium salt)
852 mg cefovecina (v obliki natrijeve soli)
Skin and soft tissue abscesses and wounds in cats:
Abscesi in rane kože in mehkega tkiva pri mačkah:
For the treatment of urinary tract infections associated with Escherichia coli.
Za zdravljenje infekcije urinarnega trakta povezane z Escherichia coli.
In cats, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 2 hours was 141 µg/ml and bioavailability approximately 99 %.
Po enkratnem subkutanem dajanju odmerka 8 mg/kg telesne teže pri mačkah, se je cefovecin hitro in obsežno resorbiral; vrh plazemske koncentracije po 2-h urah je bil 141 µg/ml in biorazpoložljivost približno 99 %.
To reconstitute, withdraw the required volume of the supplied diluent from its vial (for 23 ml vial containing 852 mg of lyophilised powder reconstitute using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitute using 4 ml of diluent) and add to the vial containing the lyophilised powder.
Za rekonstitucijo prenesite zahtevano količino vehikla iz viale z vehiklom (za 23 ml vialo, ki vsebuje 852 mg liofiliziranega praška, uporabite 10 ml vehikla, za 5 ml vialo, ki vsebuje 340 mg liofiliziranega praška, uporabite 4 ml vehikla) v vialo z liofiliziranim praškom.
When applying a proposed microbiological breakpoint of I ≤ 4 µg/ml, cefovecin resistance in S. pseudintermedius and beta-haemolytic Streptococci isolates was less than 0.02 % and 3.4 % in Prevotella intermedia isolates.
Ob dajanju predlaganega mikrobiološkega odmerka I ≤ 4 µg/ml, je bila rezistenca na cefovecin Pri S. pseudintermedius in beta-hemolitičnih Streptococci izolatih je bila rezistenca manj kot 0,02 % ter 3,4 % pri Prevotella intermedia izolatih.. Deleži na cefovecin rezistentnih izolatov pri E. coli, Prevotella oralis, Bacteroides spp.
When applying a proposed microbiological breakpoint of S ≤ 2 µg/ml, no resistance to cefovecin was detected in Pasteurella multocida, Fusobacterium spp.
Ob dajanju predlaganega mikrobiološkega odmerka S ≤ 2 µg/ml, pri Pasteurella multocida, Fusobacterium spp.
Fourteen days after administration, the mean cefovecin concentration in plasma was 5.6 μg/ml.
Štirinajst dni po dajanju je bila povprečna koncentracija cefovecina v plazmi 5,6 µg/ml.
BATCH NUMBER Lot: {number}
Lot: {številka}
STATEMENT OF ACTIVE SUBSTANCES The reconstituted solution for injection contains: 80.0 mg/ml cefovecin (as sodium salt)
Raztopina za injiciranje po rekonstituciji vsebuje: 80,0 mg/ml cefovecina (v obliki natrijeve soli)
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats.
Ponavljajoče se dajanje (8 odmeranje) petkratnega odmerka s 14-dnevnim intervalom so mlade mačke dobro prenašale.
In dogs, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 6 hours was 120 µg/ml and bioavailability approximately 99 %.
Po enkratnem subkutanem dajanju odmerka 8 mg/kg telesne teže pri psih, se je cefovecin hitro in obsežno resorbiral; vrh plazemske koncentracije po 6-ih urah je bil 120 µg/ml in biorazpoložljivost približno 99 %.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs.
Ponavljajoče se dajanje (8 odmerjanj) petkratnega odmerka s 14-dnevnim intervalom so mladi psi dobro prenašali.
and Proteus spp.
in Proteus spp.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococci spp.
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococci spp.
In addition, cefovecin exhibits in-vitro activity against Escherichia coli which is associated with canine and feline urinary tract infections.
Poleg tega cefovecin kaže in-vitro učinkovitost proti Escherichia coli, ki je povezana z infekcijo urinarnega trakta pri psih in mačkah.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococcus spp.
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococcus spp.
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
Za zdravljenje infekcije kože in mehkega tkiva vključno s piodermo, ranami in abscesi, povezanimi z okužbo s Staphylococcus pseudintermedius, β-hemolitičnimi Streptococci, Escherichia coli in/ali Pasteurella multocida.
13 mg/ml benzyl alcohol 4.45 ml water for injections
13 mg/ml benzilalkohola 4,45 ml vode za injekcije
Type I glass vial of either 10 ml or 19 ml with chlorobutyl rubber stopper sealed with an aluminium flipoff seal.
10- ali 19-mililitrska viala, steklo tipa I, s klorobutilnim gumijastim zamaškom zapečatenim z aluminijastim pokrovom.
At ten and fourteen days after administration, urine concentrations were 1.3 µg/ml and 0.7 µg/ml, respectively.
Koncentracija v urinu je bila 1,3 µg/ml 10 dni po dajanju in 0,7 µg/ml 14 dni po dajanju.
1 Lowest concentration, which completely inhibits visible growth of at least 50 % of isolates 2 Lowest concentration, which completely inhibits visible growth of at least 90 % of isolates 3 Some of these pathogens (e.g. S. aureus) exhibited natural in vitro resistance to cefovecin 4 The clinical significance of these in vitro data has not been demonstrated.
2 Najnižja koncentracija, ki povsem inhibira vidno rast najmanj 90 % izolatov
NAME OF THE VETERINARY MEDICINAL PRODUCT Diluent for Convenia
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight).
Enkratno subkutano dajanje 8 mg/kg telesne teže (1 ml na 10 kg telesne teže).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Escherichia coli
Escherichia coli pes maček
Staphylococcus pseudintermedius
Staphylococcus psudintermedius pes maček β hemolitični
Active substance: 340 mg cefovecin (as sodium salt)
340 mg cefovecina (v obliki natrijeve soli)
Each 19 ml vial of diluent contains:
Ena 19 ml viala z vehiklom vsebuje:
Dog4 Cat4
pes maček4
Powder: Type I glass vial of either 5 ml or 23 ml with butyl rubber stopper sealed with an aluminium flip-off seal.
5- ali 23-mililitrska viala, steklo tipa I, z butilnim gumijastim zamaškom zapečatenim z aluminijastim pokrovom.
Slight and transient injection site swellings were observed after the first and second administration.
Po prvem in drugem dajanju so opazili prehodno rahlo oteklino na mestu injiciranja.